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VERTICAL TRANSMISSION OF HIV
Eliminating HIV transmission through breast milk 
from women taking antiretroviral drugs
Ameena Goga and colleagues argue that frequent testing of maternal viral load is needed to 
eliminate HIV transmission through breast milk in low and middle income settings
Mothers taking antiretroviral drugs with low plasma viral loads may still transmit HIV to their breastfeeding children. Given the widely 
acknowledged benefits of breastfeeding, 
eliminating the risk of vertical transmis-
sion of HIV through breast milk must be a 
priority.
Transmission from mother to child via 
breast milk is influenced by maternal HIV 
viral load and occurs through cell-free and 
cell associated HIV-1.1 In women living 
with HIV, breast milk contains quiescent 
CD4 cells with high capacity to produce HIV 
and activated CD4 cells with replicating 
HIV, despite the presence of suppressive 
antiretroviral treatment.1 Additionally, 
transfer of maternal cells through 
breastfeeding induced microchimerism 
may establish permanent HIV reservoirs in 
breastfeeding infants.2
Nonetheless, breast milk has multiple 
immediate and long term advantages: 
it contains bacterial genes facilitating 
carbohydrate, amino acid, and energy 
metabolism3; contributes to almost 40% of 
the infant microbiome during the first 30 
days of life3; modulates the human virome4; 
reduces the risks of communicable and 
non-communicable diseases in childhood 
and adulthood5; and is associated with 
better IQ, educational attainment, and 
income at age 30 years.6 Consequently, 
there is an urgent need to eliminate 
transmission of HIV through breast milk.
Although HIV and infant feeding 
guidelines previously recommended 
avoiding breastfeeding or reducing 
duration,7-9 by 2016 modelling showed 
that in a setting where the mortality risk 
associated with avoiding breastfeeding is 
high, then 24 months of breastfeeding and 
maternal triple antiretroviral treatment 
maximises child HIV-free survival.10
Maternal antiretroviral treatment or 
infant prophylaxis during breastfeeding 
reduces the risk of HIV transmission 
through breast milk.11-14 Since 2016, all 
Global Plan priority countries (where 90% 
of the world’s pregnant women with HIV 
live) recommend lifelong antiretroviral 
treatment for pregnant and lactating 
women with HIV.15 16 Additionally, in 
2016 the World Health Organization 
recommended that  women taking 
antiretroviral drugs should breastfeed 
for at least 12 months and may continue 
breastfeeding for up to 24 months or longer 
(similar to the general population) while 
being fully supported for adherence to 
antiretroviral treatment.17
WHO guidelines for HIV plasma viral 
load monitoring are not specific to 
pregnancy and lactation: a plasma viral 
load test is recommended at six months and 
12 months, and then every 12 months.18 
Breast milk HIV viral load may be a better 
predictor of breast milk transmission 
than plasma viral load1; however, routine 
monitoring of breast milk viral load is 
costly, not widely performed, and not 
practical.
We have previously highlighted the 
increasing contribution of breast milk 
transmission to overall mother-to-child 
transmission in low and middle income 
countries because of challenges with 
early initiation of antiretroviral treatment 
and postnatal treatment adherence.19 We 
have also highlighted the contribution 
of maternal prevalent or incident HIV 
infections to the paediatric HIV case rate16 
19 20 and proposed that current strategies 
may fall short of eliminating breast 
milk transmission.19 Complementary 
interventions such as broadly neutralising 
antibodies or vaccines are needed.19 We 
have also emphasised the critical need 
to dismantle structural barriers16 and 
strengthen routine cohort monitoring of 
women living with HIV and their children 
to determine long term outcomes.21 Here we 
consider whether we can eliminate breast 
milk transmission of HIV in women taking 
antiretroviral drugs.
Risk of transmission through breast milk 
during treatment
The risk of transmitting HIV through breast 
milk is not zero if women with HIV are not 
consistently and completely suppressed at 
<50 copies/mL plasma viral load through-
out breastfeeding (see supplementary 
table 1; bmj.com). A major concern is 
that HIV transmission via breast milk 
has been described in women with previ-
ously documented viral load suppression; 
these findings may be because viral load 
measurements are taken or reviewed infre-
quently during breastfeeding.22-25
In many countries it is assumed 
that a viral load of <1000 copies/mL is 
associated with a low risk of mother to 
child transmission; however, in a South 
African study, women with a viral load of 
<1000 copies/mL at delivery accounted for 
43% of early mother to child transmission 
(median age 44 days, interquartile range 
(IQR) 42-49 days).26 If we extrapolate from 
a meta-analysis that included women 
taking antiretroviral drugs (with detectable 
or undetectable HIV viral load) and 
assume a 20% maternal HIV prevalence, 
six month mother to child transmission 
among women taking antiretroviral drugs 
KEY MESSAGES
•   Mothers taking antiretroviral drugs 
with low detectable plasma viral loads 
may still transmit HIV.
•   This is a result of challenges with 
antiretroviral treatment adherence 
and retention in care, viral load 
rebound between the viral load test 
intervals, transmission from a breast 
milk cellular reservoir, or postpartum 
or peripartum viral rebound.
•   Point-of-care technologies for viral 
load testing during pregnancy and 
breastfeeding must be scaled up and 
results acted on to reduce transmis-
sion through breast milk.
•   The utility of additional complemen-
tary interventions such as long act-
ing maternal antiretroviral drugs, 
extended prophylaxis, broadly neu-
tralising antibodies, or vaccines in 
infants whose mothers are receiving 
antiretroviral treatment needs further 
investigation.
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translates into 220 new infections per 100 
000 live births, almost four times higher 
than the mother to child transmission 
elimination target of ≤50 new infections 
per 100 000 live births.27 In this context, 
12 month mother to child transmission 
translates into 580 new paediatric HIV 
infections per 100 000 live births—more 
than 10 times the global target.27 28 In a 
study in Malawi (October 2014 to May 
2016), women taking antiretroviral drugs 
with low detectable viral load (defined as 
≥40-1000 copies/mL) contributed an excess 
of 460 new infant HIV infections annually, 
which translates into 60 additional 
infections per 100 000 births annually.29
I f  b re a s t  m i l k  m o t h e r- to - ch i l d 
transmission occurs despite maternal 
antiretroviral treatment, as a result of 
prolonged or intermittent maternal 
v i r a e m i a  i n d e p e n d e n t  o f  h e a lt h 
system and individual barriers to viral 
suppression, then the utility of additional 
or complementary interventions needs 
investigating. Potential interventions 
include long acting antiretrovirals or 
intermittently administered broadly 
neutralising antibodies or vaccines that 
could induce passive or active immunity 
without reliance on daily administration. 
Promisingly, in neonatal macaque 
models, combined administration of 
broadly neutralising antibodies PGT121 
and VRC07-523 administered within 30 
to 48 hours of oral simian HIV exposure 
mediated effect ive post- exposure 
prophylaxis in infant macaques.30 31
Risk factors for breast milk transmission
Both maternal breast milk viral load and 
plasma viral load are predictors of breast 
milk HIV transmission.23 When single dose 
nevirapine for mother and baby was the 
main intervention to prevent transmission, 
maternal plasma viral load >50 000 copies/
mL accounted for 37% (95% confidence 
interval 22% to 51%) of breast milk trans-
mission between 6 weeks and 12 months.32 
Multivariable analyses of data gathered in 
Malawi between 2014 and 2016 showed 
that maternal viral load was the only 
important predictor of transmission.29 
Consequently, frequent maternal plasma 
viral load monitoring and management 
for all pregnant and breastfeeding women 
are critical to achieve and maintain plasma 
viral load below the detection threshold.
Maternal plasma viral load monitoring 
Despite increasing access to lifelong 
antiretroviral treatment, the coverage of 
plasma viral load monitoring during breast-
feeding ranges from 38% to 98% in Global 
Plan priority countries.29 33 Non-pregnant 
adult guidelines recommend six monthly 
viral load monitoring, but this may result in 
only 31% viral load testing coverage during 
pregnancy34; reasons for this include late 
antenatal booking, limited number of ante-
natal visits, underuse of routine maternal 
viral load monitoring, stigma, and inopera-
bility of machines to measure viral load.35 36
Since 2019, some low and middle 
income countries,  such as South 
Africa, recommend viral load testing at 
antenatal care booking (or three months 
after antenatal antiretroviral treatment 
initiation or switching), at delivery, and 
then six monthly.37 If viral load is ≥1000 
copies/mL or 500-<999 copies/mL then 
counselling and repeat viral load testing 
are recommended 4-6 weeks or 8-10 weeks 
later, respectively. Infant antiretroviral 
prophylaxis is extended beyond six weeks 
or includes two drugs only if maternal 
viral load is ≥1000 copies/mL. However, 
mother-to-child transmission can occur 
when viral load is <1000 copies/mL.37 
Consequently, current recommendations 
would not eliminate the risk of breast milk 
transmission.
Regardless of setting or year, the 
prevalence  of  plasma vir al  load 
suppression among women with HIV 
taking antiretroviral drugs is suboptimal 
(see supplementary table 2; bmj.com). In 
rural Uganda, by 2015 five year retention 
in care was 90% among women starting 
antiretroviral treatment during pregnancy, 
decreasing to 67.5% if those not followed 
up were assumed to be out of care.38 Among 
women with HIV retained in care, viral 
suppression (≤400 copies/mL) was 89.6% 
(95% confidence interval 83.2% to 94.2%), 
falling to 80.7% ( 73.4% to 86.7%) among 
participants enrolled in the study, and to 
60.5% (53.6% to 67.3%), assuming that 
those not enrolled in the study were not 
suppressed.38
Scaling up viral load monitoring
Breastfeeding women are a priority popula-
tion for repeated plasma viral load meas-
urements. However, in many Global Plan 
priority countries viral load monitoring 
scale-up is limited because of logistical 
challenges relating to plasma specimen 
collection. This requires EDTA tubes, which 
are often unavailable, can break in transit, 
and require storage, a cold chain, timely 
centrifugation, and transportation to cen-
tral laboratories.39
Some countries have used dried blood 
spot or plasma separation cards to scale 
up viral load testing; however, dried blood 
spot viral load testing cannot reliably 
measure viral loads <1000 copies/mL.39 
Furthermore, the median time between 
sample collection and availability of results 
can be as long as 72 days.40 41 Investing 
in mobile health technologies for use 
by clinicians and patients may improve 
turnaround times and prompt action for 
high viral load measurements. Plasma 
separation cards have a slightly lower 
limit of detection (790.2 copies/mL (95% 
confidence interval 658.9 to1003.6 copies/
mL)),41 are cost neutral,39 and are easier to 
use.
Point-of-care viral load testing is a 
promising technology as results are 
available about two hours after sample 
collection. An open label, non-inferiority, 
randomised controlled trial found that 
point-of-care viral load monitoring with 
task shifting significantly improved 
retention and viral suppression among 
HIV infected adults in South Africa.42 
However, some point-of-care technologies 
cannot detect viral loads of <50 copies/
mL. A systematic review for the Cepheid 
GeneXpert reported a pooled sensitivity 
of 96.5% (95% confidence interval 
95.1 to 97.5) and pooled specificity of 
96.6% (92.9 to 98.4) for a treatment 
failure threshold of 1000 copies/mL; two 
publications on the Abbott m-PIMA device 
sensitivities of 95.4% (89.7 to 98.5) and 
97.1% (94.2 to 98.8) and specificities of 
96.0% (93.7 to 97.6) and 76.9% (69.8 to 
83.1) for a treatment failure threshold of 
1000 copies/mL.43
S i n c e  M a r c h  2 0 2 1  W H O  h a s 
recommended point-of-care viral load 
testing to monitor treatment in people 
living with HIV.43 Consequently, scaling 
up point-of-care viral load testing urgently 
requires implementation and integration 
into routine care, including regulatory 
approval, training, monitoring, planning 
for supply chain, reagent forecasting, 
human resources, device maintenance, 
quality assurance, and factoring in an 
additional two hour wait by patients.43 44 
Moreover, technological innovations to 
detect viral loads of <50 copies/mL are 
needed.45
Other challenges 
The prospect of viral load suppression 
exists only if mothers access antiretrovi-
ral treatment. Historically, Global Plan 
priority countries have fragile health sys-
tems. For example, in sub-Saharan Africa, 
83% of women have at least one antenatal 
visit—mainly during the second or third 
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trimester—but only 55% have at least four 
antenatal visits.46 Additionally, a meta-
analysis of 1703 antiretroviral treatment 
clinics in 35 countries (2010-14) showed 
that 37.5% had at least one antiretroviral 
treatment out of stock during a 12 month 
period.47 Similarly, in South Africa, in 
2015, 20% of 2370 facilities reported at 
least one antiretroviral or TB related medi-
cine out of stock on the day of contact and 
36% during the previous three months.48 
These challenges have increased during the 
covid-19 pandemic,49 requiring emphasis 
on maintaining sexual and reproductive 
health services in high burden and fragile 
settings.50 Modelling illustrates that a six 
month disruption in prevention of mother-
to-child transmission services during the 
covid-19 lockdown for 50% of people could 
result in 2.7 times more infants born with 
HIV in one year.51 Consequently, we need 
concerted efforts to monitor, achieve, and 
sustain undetectable viral loads through-
out breastfeeding.
Conclusion
Antiretroviral treatment effectively reduces 
viral load (and mother-to-child transmis-
sion), but for a variety of reasons many 
women do not effectively achieve and 
maintain undetectable viral loads through-
out pregnancy and breastfeeding. Current 
approaches to viral load monitoring are 
poorly implemented and the response to 
high viral load measurements is subopti-
mal; thus the risk of breast milk transmis-
sion by women taking antiretroviral drugs 
has not been eliminated. Studies reporting 
maternal plasma viral load and breast milk 
mother-to-child transmission, together or 
separately, are difficult to compare—viral 
load measurements occur at different time 
points and cut-offs for viral suppression and 
laboratory techniques differ. It is therefore 
important to rapidly scale-up other strate-
gies such as frequent point-of-care viral load 
testing coupled with timely implementation 
of additional interventions to reduce breast 
milk mother-to-child transmission among 
women taking antiretroviral drugs. However, 
the optimal frequency of viral load monitor-
ing during breastfeeding still needs inves-
tigation. Data show that viraemia occurs 
during breastfeeding, providing strong jus-
tification for investigating the utility of inter-
ventions such as long acting antiretrovirals, 
broadly neutralising antibodies, or vaccines 
despite maternal antiretroviral treatment to 
eliminate breast milk transmission.
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